We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
226
PUT
Agilent Technologies
A
$37.1B
– –
-10,000
Closed -$13K
ABT icon
227
CALL
Abbott
ABT
$175B
– –
-26,500
Closed -$417K
AKBA icon
228
Akebia Therapeutics
AKBA
$359M
– –
-30
Closed -$461
ALNY icon
229
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-2,938
Closed -$251K
AMGN icon
230
Amgen
AMGN
$198B
– –
-12,082
Closed -$2.08M
AMGN icon
231
PUT
Amgen
AMGN
$198B
– –
-19,900
Closed -$60K
BCRX icon
232
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-11,240
Closed -$62K
BCRX icon
233
PUT
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-15,000
Closed -$38K
BKD icon
234
CALL
Brookdale Senior Living
BKD
$3.58B
– –
-18,700
Closed -$7K
BUD icon
235
CALL
AB InBev
BUD
$156B
– –
-5,000
Closed -$7K
COST icon
236
CALL
Costco
COST
$417B
– –
-10,000
Closed -$6K
COST icon
237
Costco
COST
$417B
– –
-2,300
Closed -$368K
COST icon
238
PUT
Costco
COST
$417B
– –
-10,000
Closed -$16K
CPB icon
239
CALL
Campbell Soup
CPB
$6.58B
– –
-17,600
Closed -$3K
CPB icon
240
Campbell Soup
CPB
$6.58B
– –
-1,100
Closed -$57K
CPB icon
241
PUT
Campbell Soup
CPB
$6.58B
– –
-10,000
Closed -$55K
DBI icon
242
CALL
Designer Brands
DBI
$290M
– –
-20,000
Closed -$10K
DIS icon
243
Walt Disney
DIS
$170B
– –
-5,000
Closed -$531K
DIS icon
244
PUT
Walt Disney
DIS
$170B
– –
-5,000
Closed -$48K
DVAX
245
DELISTED
Dynavax Technologies
DVAX
– –
-30,795
Closed -$487K
DVAX
246
PUT
DELISTED
Dynavax Technologies
DVAX
– –
-83,600
Closed -$7K
HOG icon
247
Harley-Davidson
HOG
$2.8B
– –
-2,954
Closed -$144K
K
248
CALL
DELISTED
Kellanova
K
– –
-49,097
Closed -$9K
KHC icon
249
CALL
Kraft Heinz
KHC
$30.7B
– –
-45,100
Closed -$13K
KPTI icon
250
CALL
Karyopharm Therapeutics
KPTI
$216M
– –
-8,413
Closed -$69K
8 9
10
11 12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.